BiotechTube
Acousia Therapeutics

Acousia Therapeutics

Tübingen, Germany· Est.
acousia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $95M

Overview

Acousia Therapeutics is a clinical-stage biotech pioneer focused on creating the first pharmacological treatments for sensorineural hearing loss (SNHL), a condition affecting over 90% of hearing loss patients. Its most advanced program, ACOU085, is in a Phase 2 study for preventing cisplatin-induced hearing loss, with a parallel development path for age-related hearing loss. The company's drug candidates feature a unique dual mode of action aimed at both protecting and enhancing hearing, potentially as stand-alone or complementary therapies to devices like hearing aids. Backed by a strong academic collaboration, Acousia is positioned in a large, underserved market with no currently approved drugs.

OtologySensorineural Hearing Loss

Technology Platform

Small molecule platform with a dual mode of action (otoprotection and hearing enhancement) targeting sensory hair cells in the cochlea for the treatment of sensorineural hearing loss (SNHL).

Funding History

3
Total raised:$95M
Grant$10M
Series B$60M
Series A$25M

Opportunities

The primary opportunity is addressing the massive, completely untreated market of sensorineural hearing loss, projected to affect 2.5 billion people by 2050.
A successful drug could establish a new therapeutic category, with potential for blockbuster sales across multiple indications, from chemotherapy-induced otoprotection to chronic age-related hearing loss.
The dual mode of action allows for both acute preventative and chronic enhancement treatment paradigms.

Risk Factors

The key risk is clinical failure in the ongoing Phase 2 trial for ACOU085, as hearing loss drug development is notoriously challenging with high historical failure rates.
Regulatory uncertainty exists as no drug has been approved for SNHL, creating pathfinding challenges.
The company also faces future financing risk to fund expensive late-stage trials and potential competition from new entrants.

Competitive Landscape

The competitive landscape for pharmacological treatment of SNHL is currently very sparse, with no approved drugs, positioning Acousia as a pioneer. Competition primarily comes from hearing aid and cochlear implant companies (e.g., Sonova, Cochlear), which offer devices, not disease-modifying treatments. A handful of other biotechs are exploring gene therapies, biologics, and small molecules for hearing loss, but Acousia's advanced clinical stage with ACOU085 provides a potential first-mover advantage.

More companies in Small Molecule Drugs →More companies in Germany →